Study of VELCADEĀ® With Mitoxantrone and Etoposide for Leukemias
Phase 1/2 Completed
55 enrolled 9 charts
DREAMM 6
Phase 1/2 Completed
153 enrolled 91 charts
ImbruVeRCHOP
Phase 1/2 Completed
38 enrolled
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Phase 1/2 Completed
20 enrolled 9 charts
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase 1/2 Completed
18 enrolled
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
VELCADEĀ®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Phase 1/2 Completed
42 enrolled 8 charts
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Phase 1/2 Completed
28 enrolled 11 charts
Mel-Vel
Phase 1/2 Completed
32 enrolled 8 charts
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
Phase 1/2 Completed
107 enrolled 14 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Phase 1/2 Completed
29 enrolled
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Phase 1/2 Completed
60 enrolled 7 charts
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Phase 1/2 Completed
30 enrolled 7 charts
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Completed
50 enrolled 12 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
27 enrolled 7 charts
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Phase 1/2 Completed
37 enrolled 12 charts
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Phase 1/2 Completed
76 enrolled 6 charts
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
Phase 1/2 Completed
52 enrolled 10 charts
EMN-alloRIC
Phase 1/2 Completed
49 enrolled
ATLL
Phase 1/2 Completed
18 enrolled 13 charts
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 1/2 Completed
24 enrolled
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Completed
26 enrolled 7 charts
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Phase 1/2 Completed
12 enrolled 6 charts
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 9 charts
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Phase 1/2 Completed
58 enrolled 11 charts
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
63 enrolled 11 charts
EVOLUTION
Phase 1/2 Completed
158 enrolled 17 charts
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase 1/2 Completed
45 enrolled 12 charts
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Phase 1/2 Completed
49 enrolled 8 charts
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
Phase 1/2 Completed
40 enrolled
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
Phase 1/2 Completed
13 enrolled 5 charts
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
40 enrolled 16 charts
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Phase 1/2 Completed
35 enrolled
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Completed
50 enrolled
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
Phase 1/2 Completed
60 enrolled
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas
Phase 1/2 Completed
55 enrolled
Phase I/II Dose Escalation Study of VELCADEĀ® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Phase 1/2 Completed
102 enrolled